MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30

$12.50−0.37 (-2.87%)

Close on Nov 13, 2026Market cap $1.06BP/E –Yield –

MoonLake Immunotherapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

MoonLake Immunotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?